Logo

Whatariff.com

Global Tariffs, Categorized

🇺🇸 United States
🌍 Select Country
📦 Alkaloids of rye ergot and their derivatives; salts thereof

Alkaloids of rye ergot and their derivatives; salts thereof

HS Code:

📦

Overview

Alkaloids of rye ergot and their derivatives; salts thereof (HS Code: 293961) are a category of organic compounds derived from ergot, a fungus that grows on rye and other grains. These alkaloids, including ergotamine and ergometrine, are primarily used in the pharmaceutical industry for the production of medicines to treat migraines, induce labor, and control postpartum bleeding. Due to their potent biological activity, trade in these compounds is often subject to strict regulatory oversight to prevent misuse.

Total Trade Volume

USD 45.2 million

Data from 2022

Source

United Nations Comtrade Database

Tariff Analysis

Average Rate

5.2%

Highest Rate

12% (applied by certain developing countries)

Lowest Rate

0% (under free trade agreements like EU-Switzerland)

Common Restrictions

  • Import licenses required due to controlled substance status
  • Strict documentation for pharmaceutical use
  • Quotas in some countries to prevent overuse
  • Compliance with international drug control treaties (e.g., UN Single Convention on Narcotic Drugs)

Market Trends

Increased demand for ergot-based pharmaceuticals

Rising global demand for migraine treatments and obstetric drugs has boosted trade volumes, especially in developed markets.

2021-2022

Shift towards synthetic alternatives

Development of synthetic derivatives is reducing reliance on natural ergot alkaloids, potentially impacting future trade volumes.

2020-2022

Regulatory tightening in key markets

Stricter controls on production and distribution due to potential misuse are creating barriers to trade in some regions.

2019-2022

Recent Developments

New EU Regulation on Controlled Substances

The European Union introduced updated guidelines for the import and export of ergot alkaloids, requiring additional certification for pharmaceutical manufacturers.

January 2023

This may slow down trade processes but ensures higher safety standards, potentially benefiting compliant exporters.

Breakthrough in Synthetic Ergotamine Production

A major pharmaceutical company in the United States announced a cost-effective method for synthesizing ergotamine, reducing dependence on natural ergot sources.

September 2022

This could shift market dynamics, with reduced demand for natural ergot alkaloids in the long term.

India Expands Export Capacity

Indian manufacturers have ramped up production of ergot derivatives, targeting markets in Southeast Asia and Africa with competitive pricing.

March 2023

This is likely to increase India's share in global trade, challenging established exporters like Switzerland and Germany.